Ultragenyx Pharmaceutical’s (RARE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $60.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on RARE. Leerink Partners decreased their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Wells Fargo & Company cut their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Jefferies Financial Group reduced their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Guggenheim dropped their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a report on Monday, January 5th. Finally, TD Cowen cut their target price on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Sixteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $23.79 on Tuesday. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -4.01 and a beta of 0.16. The stock’s fifty day moving average price is $28.32 and its two-hundred day moving average price is $29.89. Ultragenyx Pharmaceutical has a one year low of $18.41 and a one year high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. During the same period in the prior year, the business posted ($1.40) EPS. The firm’s quarterly revenue was up 14.6% compared to the same quarter last year. On average, equities analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,081 shares of the company’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the sale, the chief financial officer directly owned 95,146 shares in the company, valued at $3,461,411.48. This represents a 3.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 6,227 shares of company stock worth $187,126. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RARE. Covestor Ltd grew its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the last quarter. Huntington National Bank boosted its position in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Ultragenyx Pharmaceutical by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after buying an additional 404 shares during the last quarter. Xponance Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 3.1% during the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 406 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 434 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage gene‑therapy data: Reports say Ultragenyx’s gene therapy showed sustained improvements in MPS IIIA, a positive clinical read that supports long‑term value of the pipeline. Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
• Positive Sentiment: Analyst support: HC Wainwright reiterated a “Buy” rating on RARE, which may provide baseline demand from investors who follow the firm. HC Wainwright Reiterates “Buy” Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
• Neutral Sentiment: Upcoming earnings: Ultragenyx is scheduled to report quarterly results shortly; previews (and consensus) currently expect continued negative EPS, which heightens sensitivity to the print. Ultragenyx Pharmaceutical (RARE) to Release Earnings on Thursday
• Neutral Sentiment: Insider activity: CFO Howard Horn sold ~3,061 shares (~$72k) in early February — a modest reduction in his stake that investors may note but that is not large enough, by itself, to imply a governance crisis. SEC filing: Insider sale disclosure
• Negative Sentiment: Multiple class‑action suits and investigations: Several law firms (Rosen, Bragar Eagel & Squire, Faruqi & Faruqi, Gainey McKenna & Egleston, Holzer & Holzer, Robbins Geller/RGRD and others) have filed or announced investigations alleging that Ultragenyx made false/misleading statements or omitted material facts about expected results and risks for its Phase III Orbit and Cosmic studies (setrusumab). This increases legal risk, potential distraction, and contingent liabilities for the company. Rosen Law Firm investor notice Bragar Eagel & Squire class action alert
• Negative Sentiment: Earnings risk: Analysts and previews (e.g., Zacks) highlight that Ultragenyx lacks the setup for an earnings beat and consensus expects continued losses, so an earnings miss or weak guidance could push shares lower. Zacks earnings preview

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.